Edition:
United Kingdom

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

9.14USD
7:11pm BST
Change (% chg)

$-0.18 (-1.93%)
Prev Close
$9.32
Open
$9.36
Day's High
$9.52
Day's Low
$8.70
Volume
174,506
Avg. Vol
158,744
52-wk High
$54.05
52-wk Low
$4.32

Latest Key Developments (Source: Significant Developments)

Solid Biosciences Reports $94.7 Mln IN Cash, Cash Equivalents, Available-For-Sale Securities
Monday, 13 May 2019 

May 13 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.HAD $94.7 MILLION IN CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES AS OF MARCH 31, 2019.TWO PATIENTS HAVE BEEN RANDOMIZED IN SECOND COHORT OF PHASE I/II IGNITE DMD STUDY.SHORTLY AFTER DOSING, PATIENT IN PHASE I/II IGNITE DMD STUDY TREATMENT GROUP WAS DIAGNOSED WITH A GASTROINTESTINAL INFECTION.PATIENT IN TREATMENT GROUP WAS DIAGNOSED WITH GASTROINTESTINAL INFECTION THAT WAS CLASSIFIED AS SERIOUS AE UNRELATED TO STUDY DRUG.PATIENT IN TREATMENT GROUP WAS DIAGNOSED WITH TRANSIENT DECLINE IN PLATELET COUNT THAT WAS A NON-SERIOUS AE RELATED TO STUDY DRUG.PATIENT EXPERIENCED TRANSIENT ELEVATION OF TRANSAMINASES, TRANSIENT INCREASE IN BILIRUBIN HIGHER THAN TWICE UPPER LIMIT OF NORMAL.PATIENT HAVING TRANSIENT ELEVATION OF TRANSAMINASES, TRANSIENT RISE IN BILIRUBIN REPORTED TO FDA AS SERIOUS AE RELATED TO STUDY DRUG.CONTINUES TO ENROLL PATIENTS IN IGNITE DMD PER STUDY PROTOCOL AND ANTICIPATES PROVIDING ADDITIONAL DATA LATER THIS YEAR..  Full Article

Solid Biosciences Had $122.5 Mln In Cash, Cash Equivalents & Available-For-Sale Securities As Of Dec. 31, 2018
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SOLID BIOSCIENCES INC - SOLID HAD $122.5 MILLION IN CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES AS OF DECEMBER 31, 2018.  Full Article

Solid Biosciences reports third quarter results
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SOLID BIOSCIENCES INC QUARTERLY LOSS PER SHARE $0.55.  Full Article

Solid Biosciences Qtrly Loss Per Share $0.52
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SOLID BIOSCIENCES INC QTRLY LOSS PER SHARE $0.52.SOLID BIOSCIENCES - ENDED Q2 WITH $162.8 MILLION IN CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES AS COMPARED TO $69.1 MILLION AS OF DEC 31, 2017.  Full Article

Solid Biosciences Announces FDA Removes Clinical Hold On SGT-001
Monday, 18 Jun 2018 

June 18 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES ANNOUNCES FDA REMOVES CLINICAL HOLD ON SGT-001.SOLID BIOSCIENCES INC - ACTIVITIES TO RESUME ENROLLMENT IN IGNITE DMD PHASE I/II CLINICAL TRIAL ARE UNDERWAY.SOLID BIOSCIENCES INC - SOLID NOW EXPECTS TO REPORT INITIAL DATA FROM A PRE-SPECIFIED INTERIM ANALYSIS OF IGNITE DMD IN SECOND HALF OF 2019.SOLID BIOSCIENCES - FDA LIFTED CLINICAL HOLD ON CO'S PHASE I/II CLINICAL TRIAL FOR SGT-001 FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.  Full Article

Boxer Capital Reports 6.2 Pct Passive Stake In Solid Biosciences
Friday, 18 May 2018 

May 18 (Reuters) - Solid Biosciences Inc ::BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SOLID BIOSCIENCES INC AS OF MAY 9 - SEC FILING.  Full Article

Solid Biosciences Reports Quarterly Loss Per Share Of $0.54
Thursday, 10 May 2018 

May 10 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SOLID BIOSCIENCES INC QUARTERLY LOSS PER SHARE $0.54.  Full Article

Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy
Wednesday, 18 Apr 2018 

April 18 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES PROVIDES UPDATE ON SGT-001 CLINICAL DEVELOPMENT PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY.SOLID BIOSCIENCES INC - FULL CLINICAL HOLD LETTER FROM FDA RECEIVED; COMPANY TO RESPOND IN COMING WEEKS.SOLID BIOSCIENCES INC - MANUFACTURING-RELATED PARTIAL CLINICAL HOLD ON HIGH DOSE OF SGT-001 RESOLVED.SOLID BIOSCIENCES - GOT LETTER FROM U.S. FDA RELATING TO PREVIOUSLY-ANNOUNCED FULL CLINICAL HOLD ON IGNITE DMD TRIAL.SOLID BIOSCIENCES - FULL CLINICAL HOLD WAS IN RESPONSE TO CO'S REPORT OF A SERIOUS ADVERSE EVENT IN FIRST PATIENT DOSED WITH SGT-001 IN IGNITE DMD.SOLID BIOSCIENCES - FDA SAYS CO ADDRESSED MANUFACTURING-RELATED QUESTIONS LEADING TO PARTIAL CLINICAL HOLD ON HIGH DOSE OF SGT-001 IN IGNITE DMD.  Full Article

RA Capital Management Reports A 7.9 Pct Stake In Solid Biosciences
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Solid Biosciences Inc ::RA CAPITAL MANAGEMENT, LLC REPORTS A 7.9 PERCENT STAKE IN SOLID BIOSCIENCES INC AS OF JANUARY 30, 2018 - SEC FILING.RA CAPITAL MANAGEMENT LLC SAYS SOLID BIOSCIENCES INC'S COMMON STOCK REPORTED HEREIN FOR INVESTMENT PURPOSES.  Full Article

Solid Biosciences Shares Debut About 60 Pct Above IPO Price
Friday, 26 Jan 2018 

Jan 26 (Reuters) - :SOLID BIOSCIENCES SHARES OPEN AT $25.50 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $16.00 PER SHARE.  Full Article

UPDATE 2-U.S. FDA declines to approve Sarepta's second Duchenne treatment

Aug 19 Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the risk of infection and kidney toxicity.